Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves

Otsuka Pharmaceutical terminated a deal with Akebia Therapeutics, ending the U.S. and ex-U.S. vadadustat Collaboration and License Agreements. As part of the termination of the deal, Otsuka will pay Akebia a $55 million settlement fee.